Steffen Walter
Förmögenhet: 115 100 $ per 2026-05-31
Förmögenhet: 115 100 $ per 2026-05-31
Steffen Walter is the founder of Immatics US, Inc., founded in 2015, holding the title of Chief Scientific Officer since 2015.
Dr. Walter currently holds the position of Chief Operations Officer at Immatics Biotechnologies GmbH since 2023, with the job starting in 2005 and ongoing.
Dr. Walter also holds the position of Chief Operations Officer at Immatics NV since 2023, with the job starting in 2020 and ongoing.
Dr. Walter completed a doctorate degree at Eberhard Karls Universität Tübingen.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
IMMATICS N.V. 0,01 % | 2026-03-18 | 10 000 ( 0,01 % ) | 115 100 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| IMMATICS N.V. | Verksamhetschef | 2023-03-21 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Grundare | 2015-01-01 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Verksamhetschef | 2023-03-21 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
Eberhard Karls Universität Tübingen
Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Health Technology |
Immatics NV
Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån